Department of Oncology-Pathology

Follow the chair of the department of Oncology-Pathology Lars Holmgren on twitter.

Analysing molecular characteristics and their variation during lifestyle changes, by combining digital tools, classical laboratory tests and new biomolecular measurements, could enable individualised prevention of disease. This is according to a new study from OnkPat and the University of Helsinki in Finland published in the journal Cell Systems. The researchers show what a proactive healthcare model could comprise and how it could help in maintaining good health.

A study lead by Janne Lehtiö and Lukas Orre describing a comprehensive proteogenomics analysis of lung cancer was published in Nature Cancer. The analysis reveals six molecular subtypes of lung cancer related to prognosis, oncogenic drivers and tumor immune landscape. The study indicates a future value of lung cancer subtypes and clinical proteomics for treatment stratification and precision medicine.

Olli Kallioniemi’s group and collaborators have published an article in Cancer Discovery entitled ”Implementing a functional precision medicine tumor board for acute myeloid leukemia”. This has been a 10-year effort to set up and launch functional precision cancer medicine and a molecular/functional tumor board in leukemia.

Johan Hartman with colleagues at Karolinska Institutet have developed an AI-based tool that improves the diagnosis of breast cancer tumours and the ability to predict the risk of recurrence. The greater diagnostic precision can lead to more personalised treatment for the large group of breast cancer patients with intermediate risk tumours. The results are published in the scientific journal Annals of Oncology.

Yuanyuan Zhang is the first author of an article i Cell Reports showing a specific protein complex being important for the formation of blood vessels. This can have implications for the formation of blood vessels in tumors and tumor growth.

Christofer Juhlin together with colleagues from KI, Uppsala University and Mayo Clinic (USA) has published a review article in The Lancet Diabetes & Endocrinology where they discuss genetics, pathology, radiology and clinical management of adrenal myelolipomas, a benign tumor.